| Drug ID: | Drug52 |
|---|---|
| Drug Name: | Iron |
| CID: | 23925 |
| DrugBank ID: | DB01592 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | NO |
| Other Approved: | YES |
| Identifier: | NCT01017614, , NCT03441893 |
| Molecular Formula: | Fe |
| Molecular Weight: | 55.84 g/mol |
| Isomeric SMILES: | [Fe] |
| Synonyms: | IRON; 7439-89-6; Iron, elemental; Ferrum; Iron powder; Remko; Armco iron; Ferrovac E; Ancor B; hierro |
| Phase 0: | 4 |
| Phase 1: | 19 |
| Phase 2: | 46 |
| Phase 3: | 81 |
| Phase 4: | 92 |
| Description: | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt472 | 23925 | Iron | 3040 | HBA2 | Homo sapiens (human) | Activator | |
| dt473 | 23925 | Iron | 7037 | TFRC | Homo sapiens (human) | 16564538 | None |
| dt474 | 23925 | Iron | 54583 | EGLN1 | Homo sapiens (human) | 16649251 | None |
| dt475 | 23925 | Iron | 55869 | HDAC8 | Homo sapiens (human) | 16681389 | Cofactor |
| dt476 | 23925 | Iron | 51327 | AHSP | Homo sapiens (human) | 16901899 | None |
| dt477 | 23925 | Iron | 2395 | FXN | Homo sapiens (human) | 16911956 | None |
| dt478 | 23925 | Iron | 2495 | FTH1 | Homo sapiens (human) | 17070541 | None |
| dt479 | 23925 | Iron | 2237 | FEN1 | Homo sapiens (human) | 20622253 | None |
| dt480 | 23925 | Iron | 79661 | NEIL1 | Homo sapiens (human) | 20622253 | None |
| dt481 | 23925 | Iron | 252969 | NEIL2 | Homo sapiens (human) | 20622253 | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05581420 | Oral Versus Intravenous Iron in IBD Patients With Anti-inflammatory Therapy. | NA | UNKNOWN | Leiden University Medical Center | Inflammatory Bowel Diseases | DRUG: Ferrous fumarate|DRUG: MonoFer | Details |
| NCT05456932 | Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease | PHASE4 | UNKNOWN | Leiden University Medical Center | Inflammatory Bowel Diseases|Iron-deficiency|Iron … | DRUG: Intravenous iron|DRUG: Ferric maltol|DRUG: … | Details |
| NCT07141238 | Microplastic Analysis in Pediatric Inflammatory Bowel Disease | NULL | RECRUITING | Medical University of Gdansk | Crohn Disease|Pediatric Inflammatory Bowel Diseas… | OTHER: Environmental microplastic exposure | Details |
| NCT05225545 | Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis | PHASE3 | UNKNOWN | American University of Beirut Medical Center | Anemia, Iron Deficiency|Ulcerative Colitis | DRUG: Sucrosomial Iron|DRUG: Oral Iron | Details |
| NCT05176795 | Host-microbiota-environment Interactions | NULL | TERMINATED | University Hospital, Clermont-Ferrand | Juvenile Idiopathic Arthritis|Diabetes type1|Infl… | OTHER: Stool sample | Details |
| NCT04960826 | Study of an Environmental Risk Factor in Crohn's Disease | NULL | RECRUITING | University Hospital, Lille | Inflammatory Bowel Diseases | None | Details |
| NCT04587141 | Clinical Burden of Anemia in Inflammatory Bowel Disease: Therapeutic Trial | PHASE3 | UNKNOWN | Fondazione IRCCS Policlinico San Matteo di Pavia | Iron Deficiency Anemia|Inflammatory Bowel Diseases | DRUG: Sucrosomial iron|DRUG: Ferric Gluconate|DRU… | Details |
| NCT04565821 | Feasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe | NA | ACTIVE_NOT_RECRUITING | Massachusetts General Hospital | Inflammatory Disease|Permeability; Increased|Croh… | DEVICE: IPD Probe via TNIT | Details |
| NCT04318405 | Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE). | NULL | COMPLETED | Pierre Fabre Pharma AG | Iron-Deficiency Anemia|Iron-Deficiency | DRUG: Iron isomaltoside 1000 | Details |
| NCT07380022 | Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Defense and Goodphyte Immunity in Adults With Chronic Diseases. | NA | RECRUITING | University of Thessaly | IBD|Hypertension (HTN)|Multiple Sclerosis|Anemia|… | DIETARY_SUPPLEMENT: Dietary supplement interventi… | Details |
| NCT04123990 | Study of the Prevalence of Iron Deficiency in Patients With Chronic Inflammatory Bowel Disease | NA | UNKNOWN | VIFORFRANCE | Intestinal Disease | DIAGNOSTIC_TEST: Iron status testing | Details |
| NCT03872622 | Intestinal Response Patterns to Microbial Signals | NA | COMPLETED | Sheba Medical Center | CD - Crohn's Disease | OTHER: Blood tests, intestinal biopsies, stool sa… | Details |
| NCT03466983 | A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease | PHASE4 | COMPLETED | Pharmacosmos A/S | IBD | DRUG: Iron Isomaltoside|DRUG: Ferric Carboxymalto… | Details |
| NCT03457571 | Clinical Observational Study: IBD Patients With Restless-legs-syndrome and Iron Deficiency Syndrome | NULL | COMPLETED | Charite University, Berlin, Germany | Inflammatory Bowel Diseases|Restless Legs Syndrom… | None | Details |
| NCT03376230 | Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease | NULL | TERMINATED | University Hospital, Lille | Inflammatory Bowel Diseases | OTHER: Collect of blood, urines, and intestinal b… | Details |
| NCT03282903 | The PRognostic Effect of Environmental Factors in Crohn's and Colitis | NULL | COMPLETED | University of Edinburgh | Inflammatory Bowel Diseases|Crohn Disease|Ulcerat… | None | Details |
| NCT03247816 | Feraccru® Real World Effectiveness Study in Hospital Practice ( FRESH ) | NULL | COMPLETED | Shield Therapeutics | Anemia, Iron Deficiency|Inflammatory Bowel Diseas… | None | Details |
| NCT03136419 | Microbiota and Immune microEnvironment in Pouchitis | NA | UNKNOWN | University of Padova | Pouchitis|Ulcerative Colitis|Ileal Pouch | DIETARY_SUPPLEMENT: Lactobacillus casei DG|DIETAR… | Details |
| NCT02965209 | European Novel Motorized Spiral Endoscopy Trial | NA | COMPLETED | Evangelisches Krankenhaus Düsseldorf | Disorder of Small Intestine|Gastrointestinal Hemo… | PROCEDURE: motorized spiral enteroscopy | Details |
| NCT02774057 | Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD | PHASE4 | UNKNOWN | American University of Beirut Medical Center | Iron Deficiency Anemia|Inflammatory Bowel Disease | DRUG: Captafer®|DRUG: Iron Sulfate | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 1.0 | Crohn's disease | An intestinal disease that involves inflammation located_in intestine. | disease of anatomical entity gastrointestinal system disease, intestinal disease, inflammatory bowel disease | Obiltoxaximab; Budesonide; Hydrocortisone acetate; Sulfasalazine; Ursodeoxycholic acid; Pegunigalsidase alfa; Imiglucerase; Bictegravir; Taliglucerase alfa; Etelcalcetide; Cimetidine; Desonide | Crohn's disease is a relapsing systemic inflammatory diseas… | Details |
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S08 | Strengthening barrier function | Modulation of barrier function | phosphatidylcholine (lecithin); imiquimod; mongersen | Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… | Details |
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
Environmental risk factors in inflammatory bowel disease: a population-based ca…
PMID: 25217388
Year: 2015
Relationship Type:
Association
Score: 6.3
PURPOSE: X-linked inhibitor of apoptosis (XIAP) deficiency caused by mutations in BIRC4 was originally described in male patients with X-linked lym…
Iron deficiency: the hidden miscreant in inflammatory bowel disease
PMID: 25213175
Year: 2014
Relationship Type:
Treatment
Score: 6.3
Spondyloarthritis (SpA) is a chronic inflammatory disease with either predominantly axial symptoms of the spine and sacroiliac joints (axial SpA, i…
Environmental triggers for IBD
PMID: 25048010
Year: 2014
Relationship Type:
Association
Score: 6.3
BACKGROUND AND OBJECTIVES: Faecal calprotectin is a valuable noninvasive marker for inflammatory bowel disease (IBD). The aim of our study was to de…
Special issue on the Challenges in Environmental Science and Engineering, CESE-…
PMID: 24906212
Year: 2014
Relationship Type:
Association
Score: 6.3
Comment on Gut. 2014 Jan;63(1):72-9.
Intravenous iron in inflammatory bowel disease
PMID: 24890797
Year: 2014
Relationship Type:
Association
Score: 6.3
Iron deficiency in Crohn's disease: iron supplementation or disease control?
PMID: 24726636
Year: 2014
Relationship Type:
Association
Score: 6.3
Current practice in the diagnosis and management of IBD-associated anaemia and …
PMID: 24721157
Year: 2014
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: Antibiotics are often given for inflammatory bowel disease (IBD) exacerbations, but their use among pediatric inpatients has not been as…
A novel pathway by which the environmental toxin 4-Nonylphenol may promote an i…
PMID: 24717721
Year: 2014
Relationship Type:
Mechanism
Score: 6.3
Comment in Nature. 2014 Feb 27;506(7489):441-2. Nat Rev Gastroenterol Hepatol. 2014 Apr;11(4):202. Cell Cycle. 2014;13(18):2803-4. Crohn…
Epidemiological studies of migration and environmental risk factors in the infl…
PMID: 24574798
Year: 2014
Relationship Type:
Association
Score: 6.3
The diagnosis and management of inflammatory bowel disease (IBD) in Asia can be challenging as certain infections can mimic IBD and lead to a misdia…
Environment and risk of Crohn's disease: comments on "the increasing weight of …
PMID: 24562176
Year: 2014
Relationship Type:
Clinical Trial
Score: 6.3
Iron treatment and inflammatory bowel disease: what happens in real practice?
PMID: 24486177
Year: 2014
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: Vitamin D may mediate immunomodulatory effects in patients with inflammatory bowel disease (IBD). The relationships between disease acti…
Environmental gradients predict the genetic population structure of a coral ree…
PMID: 24320929
Year: 2014
Relationship Type:
Treatment
Score: 6.3
CONTEXT: High concentration of 5-amino salicylic acid (5-ASA) in the distal ileum and colon is necessary for the treatment of inflammatory bowel dis…
Environmental factors in a population-based inception cohort of inflammatory bo…
PMID: 24315795
Year: 2014
Relationship Type:
Treatment
Score: 6.3
Ulcerative colitis and Crohn's disease are the major forms of inflammatory bowel disease. Cytokines of the tumor necrosis factor (TNF) family play a…
Gene-gene and gene-environment interactions in ulcerative colitis
PMID: 24241240
Year: 2014
Relationship Type:
Association
Score: 6.3
OBJECTIVE: To examine whether hospital type (children's hospital or generalist hospital) and surgeon specialty are associated with variations in sur…
Anti-mouse CD52 monoclonal antibody ameliorates iron-deficient anaemia in IL-10…
PMID: 24160470
Year: 2014
Relationship Type:
Treatment
Score: 6.3
Inflammatory bowel disease (IBD) is a chronic relapsing immune-mediated inflammatory disorder that affects millions of people around the world. Lept…
Expression of iron-related proteins in the duodenum is up-regulated in patients…
PMID: 24160450
Year: 2014
Relationship Type:
Mechanism
Score: 6.3
Mechanisms responsible for derangements in Fe homeostasis in chronic inflammatory conditions are not entirely clear. The aim of the present study was…
Cytokine-dependent regulation of dendritic cell differentiation in the splenic …
PMID: 24136200
Year: 2014
Relationship Type:
Association
Score: 6.3
The DC-derived chemokine CCL17, a ligand of CCR4, has been shown to promote various inflammatory diseases such as atopic dermatitis, atherosclerosis,…
Genetic isolation by environment or distance: which pattern of gene flow is mos…
PMID: 24111567
Year: 2014
Relationship Type:
Association
Score: 6.3
In classical quantitative genetics, the correlation between the phenotypes of individuals with unknown genotypes and a known pedigree relationship i…
Environmental versus geographical determinants of genetic structure in two suba…
PMID: 24102203
Year: 2014
Relationship Type:
Treatment
Score: 6.3
Erratum in PLoS One. 2013;8(7). doi:10.1371/annotation/b08ddcc9-dfdb-4fc1-b2ac-5a4af3051a91. INTRODUCTION: Members of the human intestinal micr…
Gene-environment interactions in inflammatory bowel disease: microbiota and gen…
PMID: 28839661
Year: 2012
Relationship Type:
Treatment
Score: 6.1
INTRODUCTION: Recent studies have indicated that patients are showing increased interest in playing a larger role in making decisions regarding thei…